- 1 -

SEQUENCE LISTING <110> Bayer HealthCare AG <120> Diagnostics and Therapeutics for Diseases Associated with Kallikrein 5 (KLK5) <130> BHC 04 01 025 <160> 5 <170> PatentIn version 3.2 <210> 1 <211> 1260 <212> DNA <213> Homo sapiens <400> 1 cttgtggttc ctctctactt ggggaaatca ggtgcagcgg ccatggctac agcaagaccc 60 ccctggatgt gggtgctctg tgctctgatc acagccttgc ttctgggggt cacagagcat 120 180 gttctcgcca acaatgatgt ttcctgtgac cacccctcta acaccgtgcc ctctgggagc 240 aaccaggacc tgggagctgg ggccggggaa gacgcccggt cggatgacag cagcagccgc 300 atcatcaatg gatccgactg cgatatgcac acccagccgt ggcaggccgc gctgttgcta 360 aggedeaace agetetactg eggggeggtg ttggtgeate caeagtgget geteaeggee gcccactgca ggaagaaagt tttcagagtc cgtctcggcc actactccct gtcaccagtt 420 tatgaatctg ggcagcagat gttccagggg gtcaaatcca tcccccaccc tggctactcc 480 caccetggcc actetaacga ceteatgete atcaaactga acagaagaat tegteecact 540 aaagatgtca gacccatcaa cgtctcctct cattgtccct ctgctgggac aaagtgcttg 600 gtgtctggct gggggacaac caagagcccc caagtgcact tccctaaggt cctccagtgc 660 720 ttgaatatca gcgtgctaag tcagaaaagg tgcgaggatg cttacccgag acagatagat 780 gacaccatgt tctgcgccgg tgacaaagca ggtagagact cctgccaggg tgattctggg gggcctgtgg tctgcaatgg ctccctgcag ggactcgtgt cctggggaga ttacccttgt 840 900 gcccggccca acagaccggg tgtctacacg aacctctgca agttcaccaa gtggatccag gaaaccatcc aggccaactc ctgagtcatc ccaggactca gcacaccggc atccccacct 960 gctgcaggga cagccctgac actcctttca gaccctcatt ccttcccaga gatgttgaga 1020 atgttcatct ctccagcccc tgaccccatg tctcctggac tcagggtctg cttcccccac 1080 1140 attgggctga ccgtgtctct ctagttgaac cctgggaaca atttccaaaa ctgtccaggg cgggggttgc gtctcaatct ccctggggca ctttcatcct caagctcagg gcccatccct 1200 1260 <210> 2 <211> 293

<21.2> PRT

<213> Homo sapiens

- 2 -

<400> 2 Met Ala Thr Ala Arg Pro Pro Trp Met Trp Val Leu Cys Ala Leu Ile 1.0 Thr Ala Leu Leu Gly Val Thr Glu His Val Leu Ala Asn Asn Asp 25 Val Ser Cys Asp His Pro Ser Asn Thr Val Pro Ser Gly Ser Asn Gln 40 Asp Leu Gly Ala Gly Ala Gly Glu Asp Ala Arg Ser Asp Asp Ser Ser 55 Ser Arg Ile Ile Asn Gly Ser Asp Cys Asp Met His Thr Gln Pro Trp 75 70 Gln Ala Ala Leu Leu Leu Arg Pro Asn Gln Leu Tyr Cys Gly Ala Val 90 85 Leu Val His Pro Gln Trp Leu Leu Thr Ala Ala His Cys Arg Lys Lys 105 100 Val Phe Arg Val Arg Leu Gly His Tyr Ser Leu Ser Pro Val Tyr Glu 120 Ser Gly Gln Gln Met Phe Gln Gly Val Lys Ser Ile Pro His Pro Gly 135 Tyr Ser His Pro Gly His Ser Asn Asp Leu Met Leu Ile Lys Leu Asn 150 155 Arg Arg Ile Arg Pro Thr Lys Asp Val Arg Pro Ile Asn Val Ser Ser 1.65 170 His Cys Pro Ser Ala Gly Thr Lys Cys Leu Val Ser Gly Trp Gly Thr 185 180 Thr Lys Ser Pro Gln Val His Phe Pro Lys Val Leu Gln Cys Leu Asn 200 Ile Ser Val Leu Ser Gln Lys Arg Cys Glu Asp Ala Tyr Pro Arg Gln Ile Asp Asp Thr Met Phe Cys Ala Gly Asp Lys Ala Gly Arg Asp Ser 230 Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Asn Gly Ser Leu Gln 245 Gly Leu Val Ser Trp Gly Asp Tyr Pro Cys Ala Arg Pro Asn Arg Pro 265 Gly Val Tyr Thr Asn Leu Cys Lys Phe Thr Lys Trp Ile Gln Glu Thr 285 280

Ile Gln Ala Asn Ser

290

<210> 3 <211> 18

<212> DNA

<213> artificial sequence

WO 2005/078123 PCT/EP2005/001130

-3-

<220>		
<223>	forward primer	
<400>	3	
ctgggggaca accaagag 18		
<210>	4	
<211>	20	
<212>	DNA	
<213>	artificial sequence	
•		
<220>		
<223>	reverse primer	
<400>	4	
agcacgctga tattcaagca 20		
<210>	5	
<211>	24	
<212>	DNA	
<213>	artificial sequence	
<220>		
<223>	probe	
<400>	5	
ccccaagtgc acttccctaa ggtc 24		